1. Ovarian Stimulation T, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, Kunicki M, La Marca A, Lainas G, Le Clef N, Massin N, Mastenbroek S, Polyzos N, Sunkara SK, Timeva T, Toyli M, Urbancsek J, Vermeulen N, Broekmans F. ESHRE Guideline: ovarian stimulation for IVF/ICSI (dagger). Hum Reprod Open 2020, 2020 (2): hoaa009.
2. Copperman AB, Benadiva C. Optimal usage of the GnRH antagonists: a review of the literature. Reprod Biol Endocrinol 2013, 11:20.
3. Xiao JS, Su CM, Zeng XT. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One 2014, 9 (9): e106854.
4. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016, 4: CD001750.
5. Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, van der Veen F, van Wely M. GnRH accounting versus long agonist protocols in IVF: a systematic review and meta-analysis for patient antagonist type. Hum Reprod Update 2017, 23 (5): 560-579.
6. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002, 17 (4): 874-885.
7. Roque M, Haahr T, Geber S, Esteves SC, Humaidan P. Fresh versus elective frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes. Hum Reprod Update 2019, 25 (1): 2-14.
8. Xu B, Zhou M, Wang J, Zhang D, Guo F, Si C, Leung PCK, Zhang A. Increased AIF-1-mediated TNF-alpha expression during implantation phase in IVF cycles with GnRH antagonist protocol. Hum Reprod 2018, 33 (7): 1270-1280.
9. Xu B, Wang J, Xia L, Zhang D, Wu X, Zhang A. Increased Uterine NK cell numbers and numbers in expression during the implantation phase in IVF Cycles with GnRH Antagonist Protocol. Sci Rep 2017, 7:39912.
10. Marci R, Graziano A, Lo Monte G, Piva I, Soave I, Marra E, Lisi F, Moscarini M, Caserta D. GnRH antagonists in assisted reproductive techniques: a review on the Italian experience. Eur Rev Med Pharmacol Sci 2013, 17 (7): 853-873.
11. Mokhtar S, Sadeghi MR, Akhondi MM, Zafardoust S, Badenush B, Fatemi F, Nazari F, Kamali K, Mohammadzade A. ART Outcomes in GnRH Antagonist Protocol (Flexible) and Long GnRH Agonist Protocol in Randomized Patients with Polycystic Ovary Syndrome: A Early Clinical Trial. J Reprod Infertil 2015, 16 (3): 148-154.
12. Kolibianakis EM, Venetis CA, Kalogeropoulou L, Papanikolaou E, Tarlatzis BC. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in vitro fertilization: a randomized controlled trial. Fertil Steril 2011, 95 (2): 558-562.
13. Hsieh YY, Chang CC, Tsai HD. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan J Obstet Gynecol 2008, 47 (1): 66-74.
14. Chang YL, Hsieh YY, Tsai HD. Preliminary report on the effect of a lower dose of gonadotropin-releasing hormone antagonist (cetrorelix) on ovarian hyperstimulation in lower-weight Asian women. Taiwan J Obstet Gynecol 2006, 45 (4): 317-320.
15. Kerimoglu OS, Ercan CM, Keskin U, Korkmaz C, Duru NK, Ergun A. Effect of a low dose of gonadotropin-releasing hormone antagonist on in vitro fertilization outcomes. Arch Gynecol Obstet 2013, 288 (3): 691-695.
16. Chen HJ, Lin YH, Hsieh BC, Seow KM, Hwang JL, Tzeng CR. Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation? J Assist Reprod Genet 2006, 23 (6): 289-292.
17. Wang HL, Lai HH, Chuang TH, Shih YW, Huang SC, Lee MJ, Chen SU. A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders. PLoS One 2016, 11 (4): e0154123.
18. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997, 67 (5): 917-922.
19. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P. Ovarian stimulation with HMG: results of a prospective phase III European study comparing the einizing hormone-releasing hormone (LHRH) -cetrorelix and the LHRH-agonist antagonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000, 15 (3): 526-531.
20. Engel JB, Ludwig M, Felberbaum R, Albano C, Devroey P, Diedrich K. Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a friendly approach to 'IVF'? Hum Reprod 2002, 17 (8): 2022-2026.
21. Yeung T, Chai J, Li R, Lee V, Ho PC, Ng E. A double-blind randomized controlled trial on the effect of dehydroepiandrosterone on ovarian reserve markers, ovarian response, and number of responders in normal ovarian oocytes. BJOG 2016, 123 (7): 1097-1105.
22. Xu B, Li Z, Zhang H, Jin L, Li Y, Ai J, Zhu G. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles. Fertil Steril 2012, 97 (6): 1321-1327.
23. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril. 2000, 73 (2): 314–320.
24. Engel JB, Felberbaum RE, Eilers W, Polack S, Ortmann O, Diedrich K. Clomiphene-induced LH surges and cetrorelix. Reprod Biomed Online. 2002, 5 (2): 109-111.
25. Zhang D, Xia L, Xu H, et al. Flexible Low-Dose GnRH Antagonist Protocol Is Effective in Patients With Sufficient Ovarian Reserve in IVF. Front Endocrinol (Lausanne). 2018; 9:767.